Gilead Sciences, Inc. $GILD Position Reduced by Pacer Advisors Inc.

Pacer Advisors Inc. reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 12.8% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 3,590,745 shares of the biopharmaceutical company’s stock after selling 528,977 shares during the quarter. Gilead Sciences makes up about 1.0% of Pacer Advisors Inc.’s holdings, making the stock its 25th largest holding. Pacer Advisors Inc.’s holdings in Gilead Sciences were worth $398,573,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. GoalVest Advisory LLC lifted its holdings in shares of Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares in the last quarter. Activest Wealth Management lifted its stake in Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares in the last quarter. Harbor Asset Planning Inc. acquired a new stake in Gilead Sciences during the 2nd quarter worth about $27,000. Howard Hughes Medical Institute purchased a new position in Gilead Sciences during the 2nd quarter valued at about $30,000. Finally, Putney Financial Group LLC increased its holdings in shares of Gilead Sciences by 53.4% in the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 94 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction on Friday, November 28th. The shares were sold at an average price of $126.54, for a total value of $1,265,400.00. Following the completion of the transaction, the chief executive officer owned 571,203 shares of the company’s stock, valued at $72,280,027.62. The trade was a 1.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $122.00, for a total transaction of $366,000.00. Following the completion of the sale, the chief financial officer owned 153,503 shares of the company’s stock, valued at approximately $18,727,366. This represents a 1.92% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 136,257 shares of company stock valued at $16,723,492. 0.27% of the stock is owned by corporate insiders.

Gilead Sciences Trading Up 0.5%

GILD stock opened at $125.79 on Friday. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a twelve month low of $88.57 and a twelve month high of $128.70. The company has a market cap of $156.06 billion, a P/E ratio of 19.50, a PEG ratio of 0.70 and a beta of 0.32. The business has a fifty day moving average of $122.92 and a 200-day moving average of $116.53.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The business had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same period in the previous year, the firm posted $2.02 earnings per share. Gilead Sciences’s revenue for the quarter was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.99%.

Wall Street Analyst Weigh In

A number of brokerages recently commented on GILD. Wells Fargo & Company boosted their price objective on shares of Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research report on Wednesday, December 10th. HSBC upped their price target on shares of Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a research note on Wednesday, December 10th. Citigroup boosted their target price on Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Wednesday, October 8th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a research note on Wednesday, October 8th. Finally, BMO Capital Markets set a $135.00 price target on Gilead Sciences in a report on Tuesday, November 25th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $131.54.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.